Journal article 474 views 63 downloads
The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses
Zack Saud,
Victoria J. Tyrrell,
Andreas Zaragkoulias 
,
Majd B. Protty ,
Evelina Statkute,
Anzelika Rubina,
Kirsten Bentley ,
Daniel A. White,
Patricia Dos Santos Rodrigues ,
Robert C. Murphy,
Harald Köfeler,
William Griffiths ,
Jorge Alvarez-Jarreta ,
Richard William Brown ,
Robert G. Newcombe,
James Heyman,
Manon Pritchard,
Robert WJ. Mcleod ,
Arvind Arya,
Ceri-Ann Lynch,
David Owens,
P Vince Jenkins,
Niklaas J. Buurma ,
Valerie B. O’Donnell,
David W. Thomas ,
Richard J. Stanton
,
Majd B. Protty ,
Evelina Statkute,
Anzelika Rubina,
Kirsten Bentley ,
Daniel A. White,
Patricia Dos Santos Rodrigues ,
Robert C. Murphy,
Harald Köfeler,
William Griffiths ,
Jorge Alvarez-Jarreta ,
Richard William Brown ,
Robert G. Newcombe,
James Heyman,
Manon Pritchard,
Robert WJ. Mcleod ,
Arvind Arya,
Ceri-Ann Lynch,
David Owens,
P Vince Jenkins,
Niklaas J. Buurma ,
Valerie B. O’Donnell,
David W. Thomas ,
Richard J. Stanton
Journal of Lipid Research, Volume: 63, Issue: 6, Start page: 100208
Swansea University Author:
William Griffiths
-
PDF | Version of Record
© 2022 THE AUTHORS. This is an open access article under the CC BY license
Download (1.63MB)
DOI (Published version): 10.1016/j.jlr.2022.100208
Abstract
The lipid envelope of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an essential component of the virus; however, its molecular composition is undetermined. Addressing this knowledge gap could support the design of antiviral agents as well as further our understanding of viral-host...
| Published in: | Journal of Lipid Research |
|---|---|
| ISSN: | 0022-2275 |
| Published: |
Elsevier BV
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa60471 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
The lipid envelope of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an essential component of the virus; however, its molecular composition is undetermined. Addressing this knowledge gap could support the design of antiviral agents as well as further our understanding of viral-host protein interactions, infectivity, pathogenicity, and innate immune system clearance. Lipidomics revealed that the virus envelope comprised mainly phospholipids (PLs), with some cholesterol and sphingolipids, and with cholesterol/phospholipid ratio similar to lysosomes. Unlike cellular membranes, procoagulant amino-PLs were present on the external side of the viral envelope at levels exceeding those on activated platelets. Accordingly, virions directly promoted blood coagulation. To investigate whether these differences could enable selective targeting of the viral envelope in vivo, we tested whether oral rinses containing lipid-disrupting chemicals could reduce infectivity. Products containing PL-disrupting surfactants (such as cetylpyridinium chloride) met European virucidal standards in vitro; however, components that altered the critical micelle concentration reduced efficacy, and products containing essential oils, povidone-iodine, or chlorhexidine were ineffective. This result was recapitulated in vivo, where a 30-s oral rinse with cetylpyridinium chloride mouthwash eliminated live virus in the oral cavity of patients with coronavirus disease 19 for at least 1 h, whereas povidone-iodine and saline mouthwashes were ineffective. We conclude that the SARS-CoV-2 lipid envelope i) is distinct from the host plasma membrane, which may enable design of selective antiviral approaches; ii) contains exposed phosphatidylethanolamine and phosphatidylserine, which may influence thrombosis, pathogenicity, and inflammation; and iii) can be selectively targeted in vivo by specific oral rinses. |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
R. J. S. was partly funded by UK Research and Innovation/National Institute of Health Research through the UK Coronavirus Immunology Consortium. V. J. T., D. W., M. P., and P. D. S. R. are supported in part by the Welsh Government/EU Ser Cymru Programme. M. B. P. was funded by a Wellcome Trust GW4CAT Training Fellowship (grant no.: 216278/Z/19/Z), and R. M. and M. J. P. are Welsh Clinical Academic Training Fellows. V. O. D. was a Royal Society Wolfson Merit Award Holder. A. Z. was funded by the Biotechnology and Biological Sciences Research Council (grant no.: BB/W003376/1). |
| Issue: |
6 |
| Start Page: |
100208 |